- Home
- CURI vs KPTI Comparison
CURI vs KPTI Comparison
Compare CURI & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURI
- KPTI
- Stock Information
- Founded
- CURI 2015
- KPTI 2008
- Country
- CURI United States
- KPTI United States
- Employees
- CURI N/A
- KPTI N/A
- Industry
- CURI Movies/Entertainment
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- CURI Consumer Discretionary
- KPTI Health Care
- Exchange
- CURI Nasdaq
- KPTI Nasdaq
- Market Cap
- CURI 100.4M
- KPTI 103.5M
- IPO Year
- CURI N/A
- KPTI 2013
- Fundamental
- Price
- CURI $1.54
- KPTI $0.64
- Analyst Decision
- CURI Strong Buy
- KPTI Strong Buy
- Analyst Count
- CURI 1
- KPTI 4
- Target Price
- CURI $3.00
- KPTI $5.00
- AVG Volume (30 Days)
- CURI 168.1K
- KPTI 1.0M
- Earning Date
- CURI 11-06-2024
- KPTI 11-05-2024
- Dividend Yield
- CURI 6.49%
- KPTI N/A
- EPS Growth
- CURI N/A
- KPTI N/A
- EPS
- CURI N/A
- KPTI N/A
- Revenue
- CURI $51,775,000.00
- KPTI $148,442,000.00
- Revenue This Year
- CURI N/A
- KPTI $6.67
- Revenue Next Year
- CURI $9.18
- KPTI $8.58
- P/E Ratio
- CURI N/A
- KPTI N/A
- Revenue Growth
- CURI N/A
- KPTI 1.77
- 52 Week Low
- CURI $0.45
- KPTI $0.63
- 52 Week High
- CURI $3.00
- KPTI $1.95
- Technical
- Relative Strength Index (RSI)
- CURI 37.16
- KPTI 25.28
- Support Level
- CURI $1.47
- KPTI $0.75
- Resistance Level
- CURI $1.72
- KPTI $0.83
- Average True Range (ATR)
- CURI 0.09
- KPTI 0.05
- MACD
- CURI -0.01
- KPTI -0.01
- Stochastic Oscillator
- CURI 18.42
- KPTI 4.21
About CURI CuriosityStream Inc.
CuriosityStream Inc is a media and entertainment company. It offers premium video programming across the principal categories of factual entertainment, including science, history, society, nature, lifestyle, and technology. Its mission is to provide premium real entertainment that informs, enchants, and inspires. Its product and services are Direct to Consumer Business, Partner Direct Business, Bundled Distribution, Content Licensing, Enterprise Subscriptions, and Others. The majority of the revenue comes from the Direct to direct-to-consumer business.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.